SCHEMBL12190843

SCHEMBL12190843

Cc1cc(-c2cncc(C(=O)NCCc3ccccc3)c2)cc(C)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.56
NPC1 O15118 8/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
POLB P06746 2/20 0.54
SCN2A Q99250 2/20 0.53
SCN10A Q9Y5Y9 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.49
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
EPHX2 P34913 1/20 0.48
HDAC2 Q92769 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
HDAC6 Q9UBN7 2/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12190896 0.85 SCN2A (0.61) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL12190922 0.83 LMNA (0.60) SMN1; SMN2MEN1KMT2APOLBLMNA
SCHEMBL9011235 0.83 RAB9A (0.73) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL12190912 0.80 CCNC (0.53) RAB9ANPC1MEN1KMT2ASCN10A
SCHEMBL12191114 0.80 DGAT2 (0.58) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL12190918 0.80 HDAC1 (0.69) SMN1; SMN2MEN1KMT2APOLBSCN2A
SCHEMBL12190839 0.80 HDAC1 (0.57) SMN1; SMN2MEN1KMT2APOLBSCN2A
SCHEMBL9972948 0.78 RAB9A (0.61) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL12191001 0.78 RAB9A (0.56) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL9011163 0.77 POLB (0.58) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030336-B2 Nicotinamide-based kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2011-10-04 US disclosed
US-8030336-B2 Nicotinamide-based kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2011-10-04 US disclosed
US-20070060619-A1 Nicotinamide-based kinase inhibitors CYTOPIA PTY LTD (AU) 2007-03-15 US disclosed
US-20070060619-A1 Nicotinamide-based kinase inhibitors CYTOPIA PTY LTD (AU) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060619-A1 Nicotinamide-based kinase inhibitors NADK, NAMPT, PDXK RAB9A 1444/4885NPC1 825/4885SMN1; SMN2 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.